Shrinks In Sneakers

Tag: psychology

  • Embracing the End: Why Psychedelics Are the Future of Compassionate End-of-Life Care

    Embracing the End: Why Psychedelics Are the Future of Compassionate End-of-Life Care

    One of the earliest and most logical places to introduce psychedelic medicine is for end of life and palliative care. It does not come with the same problems as treating patients with depression or other psychiatric disorders as the treatment will be time limited. 

    Here are some of the benefits based on the current research

    1. Psychological Benefits

    • Reduction in Anxiety and Depression: Several studies, particularly those using psilocybin, have demonstrated significant reductions in anxiety and depression in patients with terminal illnesses like cancer. These effects are often long-lasting, with benefits persisting for months after a single treatment session.
      • A notable 2016 study published in The Journal of Psychopharmacology showed that 80% of cancer patients treated with psilocybin experienced significant reductions in anxiety and depression, with some reporting a renewed sense of life meaning.

    2. Spiritual and Existential Distress

    • Psychedelics, especially psilocybin and LSD, are reported to induce mystical or transcendent experiences, which many patients describe as spiritually meaningful. This has been associated with reduced existential distress and increased acceptance of mortality.
      • Participants in several trials often report a greater sense of interconnectedness, enhanced life meaning, and a reduced fear of death.

    3. Enhanced Quality of Life

    • Beyond symptom relief, psychedelics have shown potential in improving overall quality of life. Patients often report improvements in emotional well-being, social connections, and the ability to engage with their loved ones, which are critical in end-of-life care.
      • In studies, patients often describe a greater ability to process emotions related to their diagnosis, leading to enhanced peace and emotional resilience.

    4. Safety and Low Abuse Potential

    • When administered in controlled, therapeutic settings, psychedelics like psilocybin are generally well-tolerated with minimal side effects. This contrasts with the stigma and misconceptions surrounding their use. Studies also emphasize the low risk of dependence or misuse, particularly in these clinical contexts.

    5. Mechanism of Action

    • Psychedelics are believed to work by temporarily disrupting the default mode network (DMN) in the brain, which is involved in self-referential thinking and rumination. This disruption may facilitate shifts in perspective, reducing the obsessive focus on illness and death that can fuel anxiety and depression in terminal patients.

    6. Therapeutic Process

    • Psychedelics are not stand-alone treatments but are typically administered in the context of guided therapy sessions. These sessions help patients integrate their psychedelic experiences, allowing them to explore their fears, emotions, and relationships in a supportive environment.

    7. Legal and Regulatory Considerations

    • Despite promising results, the legal status of psychedelics limits widespread use. However, growing clinical interest has led to “compassionate use” cases and expanded research protocols under FDA guidelines, signaling potential shifts in policy.

    Overall, the evidence suggests that psychedelics, particularly psilocybin, could provide significant psychological and existential relief for individuals facing end-of-life distress, although more research is needed to fully understand the scope of benefits. 

  • The parallels between the psychiatric asylums and modern inpatient psychiatric treatment 

    The parallels between the psychiatric asylums and modern inpatient psychiatric treatment 

    The history of psychiatric asylums is a dark chapter in mental health care, yet the more I reflect on it, the more I see troubling parallels between the asylum era and our modern system of inpatient psychiatric treatment.

    Asylums, in their earliest forms, were created with good intentions: to provide care for those with severe mental illnesses and intellectual disabilities who could not be safely or adequately treated in their communities. However, as these institutions became overcrowded, underfunded, and poorly staffed, they devolved into places of neglect, abuse, and suffering. The eventual closures of these institutions were a necessary response to the horrific conditions exposed, but the underlying issues didn’t disappear. They merely shifted.

    Today, many of the same challenges persist in our modern inpatient psychiatric system. Patients with severe mental illnesses or disabilities still require long-term care, but instead of asylums, they are placed in short-term facilities. These hospitals are often understaffed and overburdened, operating under financial pressures to prioritize quick turnover rather than long-term recovery. It’s not uncommon for patients to be admitted, stabilized just enough for discharge, and then readmitted within weeks—sometimes even days—because the core issues remain unaddressed.

    In both the asylums of the past and the short-term psychiatric hospitals of today, patients often receive the same types of medications and therapies. The difference is that today’s treatment settings operate under stricter legal frameworks aimed at preserving patient rights, but the lack of continuity and depth in treatment results in a revolving door of care. Rather than focusing on sustained recovery, the focus is often on crisis management and meeting insurance-imposed timelines.

    This cycle is problematic for patients and clinicians alike. For patients, it results in frustration, instability, and a lack of meaningful progress. For healthcare workers, it leads to burnout, similar to what was seen in the asylum era. The system, despite its modern façade, hasn’t evolved enough to address the long-term needs of individuals with severe mental illnesses. Until we invest in creating a system that prioritizes long-term, comprehensive care, we risk repeating the mistakes of the past—only this time without the walls of the asylum to contain the issue.

  • Have We Truly Moved Beyond the Asylum? Rethinking Modern Mental Health Care

    Have We Truly Moved Beyond the Asylum? Rethinking Modern Mental Health Care

    It’s that time of year when fall festivities begin, bringing with them the comforting embrace of pumpkin spice and the thrill of Halloween fun. Over the weekend, I visited Pennhurst Asylum to experience its haunted attractions. While it’s all good fun and purely fictional, it stands in stark contrast to the true horrors that once existed within asylums. I learned a great deal about Pennhurst’s tragic history—how it was eventually shut down due to horrendous living conditions, rampant abuse, lack of proper care, and the heartbreaking deaths of many patients.

    The concept of an asylum was originally born from good intentions. There was a need for a controlled, carefully monitored environment where individuals with severe mental illnesses and intellectual disabilities could receive care when it couldn’t be provided at home. However, these institutions quickly became overcrowded and severely underfunded, leading to dangerous conditions and substandard care. When you listen to interviews with former staff, it becomes painfully clear that most of them genuinely wanted to help, but they were overwhelmed by the lack of resources and growing patient populations, which ultimately led to burnout and a breakdown in the system.

    What struck me the most during my visit is how little our modern mental health system has progressed beyond the asylum model. While the walls of these institutions may have crumbled, the systemic issues remain. We still face a severe shortage of resources, and we still have large populations of patients with serious mental illnesses or intellectual disabilities, conditions that we have yet to find effective cures for. The difference now is that the burden has shifted to short-term inpatient facilities, where it’s not uncommon to treat and discharge the same patient multiple times within a single month. These patients deserve a place where they can receive long-term, consistent treatment and careful observation—certainly more than just five to seven days.

    The problem is multifaceted. It involves the tension between patients’ rights, insurance companies, and the pressure to generate profit from the care delivered. We find ourselves in a vicious cycle where patients make minimal progress with short-term interventions, are discharged, and quickly decompensate upon returning to the community. In many ways, the same forms of therapy and the same medications that were used in asylums are being employed today in these short-term facilities.

    While I’d like to be hopeful, I can’t help but see the striking parallels between our current system and the asylums of the past. Unfortunately, the evolution of mental health care feels more like a lateral move than a leap forward. Until we address the root issues—underfunding, understaffing, and the over-reliance on short-term fixes—it’s difficult to imagine real progress.

  • Breakthrough in Bipolar Detection: Promising, But Is It Practical

    Breakthrough in Bipolar Detection: Promising, But Is It Practical

    While this study underscores the critical need for early detection of bipolar disorder to prevent misdiagnosis and improper treatment, the advanced MRI techniques and extensive behavioral assessments it highlights may not be practical in most current clinical settings. This is often the challenge with such research: although it can enhance diagnostic accuracy, its real-world application remains limited.

    Link to Article: https://pubmed.ncbi.nlm.nih.gov/39069165/

  • FDA warns patients and health care providers about potential risks associated with compounded ketamine

    FDA warns patients and health care providers about potential risks associated with compounded ketamine

    The FDA has issued a warning to patients and healthcare providers regarding the potential risks of compounded ketamine products, including oral formulations, used for psychiatric disorders. These products, often compounded outside of FDA oversight, can pose serious safety concerns such as inconsistent dosing, contamination, and lack of proven efficacy. The FDA emphasizes that while ketamine is approved for anesthesia and certain treatments, compounded versions may not meet the same quality standards, leading to unpredictable outcomes. Patients are urged to consult with their healthcare providers to explore safer, FDA-approved treatment options for psychiatric conditions.

    Link to FDA press release: https://www.fda.gov/drugs/human-drug-compounding/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine

  • Facing Treatment-Resistant Depression? Your Risk of Death Could Skyrocket

    Facing Treatment-Resistant Depression? Your Risk of Death Could Skyrocket

    A recent population-based cohort study examining cause-specific mortality in treatment-resistant major depression (TRD) revealed significant findings about the increased risks faced by those with TRD. The study, which analyzed data from over 176,000 Finnish patients diagnosed with major depressive disorder (MDD), found that approximately 11% of these patients developed TRD, meaning they did not respond to at least two adequate treatment trials.

    Key findings include that patient’s with TRD had a 17% higher overall mortality rate compared to non-TRD patients. The study highlights that much of this elevated mortality stems from external causes, with TRD patients facing nearly double the risk of suicide and a 27% higher chance of accidental death. Factors like male gender, psychotic depression, and rapid failure of initial treatments were linked to higher mortality risks.

    These findings highlight the importance of early intervention and aggressive treatment strategies for those diagnosed with TRD. The study suggests that clinicians should monitor patients closely and consider alternative therapeutic interventions, such as electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS), when conventional treatments fail​

    Link to the article: https://www.sciencedirect.com/science/article/pii/S0165032724015490?via%3Dihub

  • The Dirty Little Secret They Won’t Tell You About Psychedelics

    The Dirty Little Secret They Won’t Tell You About Psychedelics

    It’s obvious to me, but I think the public, including many of our patients, remains unaware of a crucial truth: Psychedelics will not cure your depression, your PTSD, or your difficult life circumstances.

    There’s a growing wave of enthusiasm around psychedelics as miracle cures for mental health conditions, but the hard reality is that the evidence just doesn’t back it up—at least not yet. Even if you find yourself on the hopeful side, believing we desperately need alternatives to alleviate people’s suffering, the reported benefits of these substances have not been validated by large, rigorous, randomized controlled trials. The buzz around psychedelics often overshadows the fact that they lack the necessary scientific backing to support their mainstream use in treating complex mental health issues like depression or PTSD.

    Let’s not ignore the financial stakes here either: The people promoting these drugs stand to make billions of dollars. There’s a lot of money on the table, and many in the academic community are rallying behind these companies. But we should ask ourselves—are they doing so because of solid science or because of the potential financial windfall?

    These drugs have been around for decades, yet one consistent truth I’ve observed in every person I’ve known who’s used them is this: You must use them repeatedly, and they almost always experience a relapse of symptoms over time. There’s no permanent fix here, just a temporary reprieve, if even that.

    We can draw parallels with other treatments like ECT (electroconvulsive therapy) and ketamine. Both have shown promise in certain cases, but I’ve yet to see anyone cured by these treatments. We often perform maintenance ECT and maintenance ketamine therapy for this very reason. Just like psychedelics, they might offer temporary relief, but they don’t provide long-term solutions without ongoing interventions.

    I understand this may come off as cynical, but I’ve seen too many people fall for the hype, only to be disappointed later. People far more charismatic than me will try to convince you that psychedelics will cure everything that ails you—for a hefty price tag. Don’t buy into it without questioning the science and the motives behind the push.

  • Suicide Pods: A Grim Symptom of Our Global Mental Health Crisis

    Suicide Pods: A Grim Symptom of Our Global Mental Health Crisis

    Several individuals were arrested following the death of a 64-year-old American woman who used a controversial “suicide pod” in Switzerland. The device, known as Sarco, enables individuals to end their lives by releasing nitrogen gas, causing a painless death through oxygen deprivation. The incident occurred in the Schaffhausen canton near the Swiss-German border, supervised by a Swiss assisted suicide organization, The Last Resort

    Authorities detained several people involved, including Florian Willet, the co-president of The Last Resort, a journalist, and others, on charges of inducing and aiding suicide. Although assisted suicide is legal in Switzerland, the use of the Sarco pod has raised questions about its compliance with safety regulations and the legality of nitrogen use in this contex

    If you or a loved one is suffering there is hope:

    Help is available 

    Speak with someone today 

    988 Suicide and Crisis Lifeline

    Languages: English, Spanish

    Hours: Available 24 hours

  • Navigating First-Episode Psychosis: A Delicate Balance

    Navigating First-Episode Psychosis: A Delicate Balance

    In my practice, I encounter many cases of first-episode psychosis, a critical period that requires thoughtful and precise intervention. The decisions made during this time can set a patient on the path to long-term recovery or, unfortunately, towards a lifetime of challenges.

    There are a few guiding principles I always adhere to:

    1. Most antipsychotics can be effective, but it’s important to choose carefully.
    2. Lower doses often suffice to achieve remission in first-episode psychosis. Starting with a medication that has a lower risk of cardiometabolic side effects and weight gain is crucial, especially for young patients. They shouldn’t be burdened with long-term physical side effects as they navigate their recovery.

    Predicting whether a patient will experience a single episode or develop a chronic condition like schizophrenia is challenging. While family history and substance use, particularly cannabis, can provide clues, there is still uncertainty.

    I believe that after 6-12 months of treatment, it’s worth considering tapering the antipsychotic to the lowest effective dose, with a careful eye on any signs of relapse. Unfortunately, what I often see is that both patients and clinicians overlook the subtle signs of relapse because they’ve mutually decided to discontinue the medication. By the time I see them again, the situation has worsened.

    Early psychosis treatment requires a delicate balance between managing symptoms and minimizing long-term side effects, all while keeping a close watch for signs of relapse. Careful planning is key to setting patients on the best path forward.

  • Semaglutide: The Diabetes Drug with a Life-Saving Twist Against Opioid Overdose

    Semaglutide: The Diabetes Drug with a Life-Saving Twist Against Opioid Overdose

    A recent study published in JAMA Network Open investigated the relationship between semaglutide, a medication commonly used for type 2 diabetes (T2D), and the risk of opioid overdose in patients with both T2D and opioid use disorder (OUD). The researchers analyzed the health records of over 33,000 individuals, finding that those taking semaglutide had a significantly lower risk of opioid overdose compared to those using other diabetes medications. Semaglutide reduced overdose risk by as much as 58% when compared to insulin, and by 54% compared to metformin.

    The findings suggest that semaglutide may have protective effects in people with OUD and T2D, although more research is needed to confirm the mechanisms behind these effects and to validate the results through clinical trials. Researchers emphasized that these promising outcomes highlight the potential therapeutic value of semaglutide beyond diabetes management, though the study faced limitations due to its observational design and the possibility of uncontrolled variables.

    Further research is required to understand how semaglutide could be integrated into treatment strategies for opioid use disorder​

    Link to the article: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2824054?utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamanetworkopen&utm_content=wklyforyou&utm_term=092524&adv=null